Targeting NE activity [121] and pro-inflammatory cytokine production [122] may also represent therapeutic strategies for MS (Figure 4), but these are not directed against specific neutrophil subsets linked to MS pathogenesis. The gene discussed is ELANE; the disease is myeloid sarcoma.